फ़्रांस - फ़्रेंच - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

sandoz - bicalutamide 50 - comprimé - 50,00 mg - pour un comprimé > bicalutamide 50,00 mg - antagonistes hormonaux et molecules apparentees - classe pharmacothérapeutique : antagonistes hormonaux et molecules apparentees, anti-androgenes, code atc : l02bb03.bicalutamide sandoz est un médicament qui appartient à la classe des «anti-androgènes». il modifie certains des effets des hormones sexuelles masculines.bicalutamide sandoz est utilisé pour le traitement du cancer de la prostate, soit : en monothérapie pour les tumeurs dites de stade « localement avancé », en association avec d'autres traitements tels que castration chirurgicale ou médicaments qui réduisent le taux d'androgènes dans le corps pour les tumeurs dites de stade « avancé ».

फ़्रांस - फ़्रेंच - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

teva sante - bicalutamide 50 - comprimé - 50,0 mg - pour un comprimé > bicalutamide 50,0 mg - a - classe pharmacothérapeutique : anti-androgènes - code atc : l02bb03bicalutamide teva contient un médicament appelé bicalutamide. il appartient à un groupe de médicaments appelés « anti-androgènes ». le bicalutamide est utilisé avec d’autres traitements pour traiter le cancer de la prostate. il agit en bloquant les effets des hormones masculines comme la testostérone.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

major pharmaceuticals - bicalutamide (unii: a0z3nau9dp) (bicalutamide - unii:a0z3nau9dp) - bicalutamide 50 mg - bicalutamide tablets 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (lhrh) analog for the treatment of stage d 2 metastatic carcinoma of the prostate. bicalutamide tablets 150 mg daily is not approved for use alone or with other treatments [see clinical studies (14.2)]. bicalutamide is contraindicated in: bicalutamide is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tablet’s components. hypersensitivity reactions including angioneurotic edema and urticaria have been reported. bicalutamide has no indication for women, and should not be used in this population. bicalutamide can cause fetal harm when administered to a pregnant woman [see use in specific populations (8.1)]. risk summary bicalutamide is contraindicated for use in pregnant women because it c

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - bicalutamide (unii: a0z3nau9dp) (bicalutamide - unii:a0z3nau9dp) - bicalutamide 50 mg - bicalutamide tablets, usp 50 mg daily are indicated for use in combination therapy with a luteinizing hormone-releasing hormone (lhrh) analog for the treatment of stage d2 metastatic carcinoma of the prostate. bicalutamide tablets, usp 150 mg daily are not approved for use alone or with other treatments [see clinical studies (14.2)]. bicalutamide is contraindicated in: - hypersensitivity bicalutamide is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tablet’s components. hypersensitivity reactions including angioneurotic edema and urticaria have been reported. - women bicalutamide has no indication for women, and should not be used in this population. - pregnancy bicalutamide can cause fetal harm when administered to a pregnant woman [see use in specific populations (8.1)]. risk summary bicalutamide is contraindicated for use in pregnant women because it can cause fetal harm. bicalutamide is not indicated for use in females. there are no human data on t

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

bryant ranch prepack - bicalutamide (unii: a0z3nau9dp) (bicalutamide - unii:a0z3nau9dp) - bicalutamide 50 mg - bicalutamide tablets 50 mg daily are indicated for use in combination therapy with a luteinizing hormone-releasing hormone (lhrh) analog for the treatment of stage d2 metastatic carcinoma of the prostate. bicalutamide tablets 150 mg daily are not approved for use alone or with other treatments [see clinical studies (14.2) ]. bicalutamide tablets are contraindicated in: - hypersensitivity bicalutamide tablets are contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tablet’s components. hypersensitivity reactions including angioneurotic edema and urticaria have been reported. - women bicalutamide tablets have no indication for women, and should not be used in this population. - pregnancy bicalutamide tablets can cause fetal harm when administered to a pregnant woman [see use in specific populations (8.1) ]. risk summary bicalutamide is contraindicated for use in pregnant women because it can cause fetal harm. bicalutamide is not indicated for use in f

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - bicalutamide, quantity: 50 mg - tablet, film coated - excipient ingredients: macrogol 400; lactose monohydrate; povidone; titanium dioxide; hypromellose; magnesium stearate; sodium starch glycollate type a - treatment of advanced prostate cancer in combination with lhrh agonist therapy. prevention of disease flare associated with the use of lhrh agonists.

बेल्जियम - डच - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - bicalutamide 50 mg - filmomhulde tablet - 50 mg - bicalutamide 50 mg - bicalutamide

फ़्रांस - फ़्रेंच - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

cristers - bicalutamide 50 mg - comprimé - 50 mg - pour un comprimé > bicalutamide 50 mg - antiandrogenes - bicalutamide cristers 50 mg, comprimé pelliculé est un anti-androgène.ce médicament est préconisé dans le traitement de certaines affections de la prostate .

कनाडा - फ़्रेंच - Health Canada

pharmascience inc - bicalutamide - comprimé - 50mg - bicalutamide 50mg - antineoplastic agents

कनाडा - फ़्रेंच - Health Canada

pro doc limitee - bicalutamide - comprimé - 50mg - bicalutamide 50mg - antineoplastic agents